SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CVTX - CV Therapeutics, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: C.Carlos who wrote (358)12/7/2008 7:19:15 PM
From: Biomaven   of 411
 
The labeling is now first line, but I believe the reality is that doctors will use the familiar (and cheap) set of existing drugs (beta-blockers etc.) as first line, and reserve Ranexa for the patients who are not responsive to the older therapies.

I do believe this is the sort of drug that will steadily ramp up over several years given decent sales and marketing. Sometimes the market underestimates that sort of drug. I suspect the market also underestimates potential European sales.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News